Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?

Paulina Vidal-Cevallos; Norberto Chávez-Tapia

doi:10.1016/j.medj.2024.03.013

Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?

Med. 2024 May 10;5(5):375-376. doi: 10.1016/j.medj.2024.03.013.

Authors

Paulina Vidal-Cevallos¹, Norberto Chávez-Tapia²

Affiliations

¹ Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, Toriello Guerra, 14050 Mexico City, Mexico.
² Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, Toriello Guerra, 14050 Mexico City, Mexico. Electronic address: nchavezt@medicasur.org.mx.

PMID: 38733968
DOI: 10.1016/j.medj.2024.03.013

Abstract

The most important factor associated with liver-related mortality in NAFLD is liver fibrosis. There is no approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) or liver fibrosis. In the MAESTRO-NASH trial, Harrison et al.¹ demonstrated the efficacy of resmetirom, a selective THR-β agonist, for the treatment of MASH and liver fibrosis at 52 weeks.

MeSH terms

Chalcones
Fatty Liver / metabolism
Humans
Liver Cirrhosis* / drug therapy
Liver Cirrhosis* / metabolism
Non-alcoholic Fatty Liver Disease / drug therapy
Non-alcoholic Fatty Liver Disease / metabolism
Propionates

Substances

2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid
Propionates
Chalcones